|
|
Article: New Data Presented at WCTRIMS* Supports the Importance of Early and Sustained Treatment with Betaseron(R).
- Article from:
- PR Newswire
- Article date:
- September 19, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Earlier treatment initiation and longer exposure to Betaseron was associated with improved long-term outcomes in multiple sclerosis
MONTREAL, Sept. 19 /PRNewswire/ -- Data presented at the World Congress on Treatment and Research in Multiple Sclerosis (WCTRIMS) demonstrated that early initiation of Betaseron(R) (interferon beta-1b) treatment had a greater impact on long-term outcomes, when compared to delayed treatment. (i)
The study, sponsored by Bayer HealthCare Pharmaceuticals, used data from the 16-Year Long-Term Follow-up Study of Betaseron to investigate the relationship between timing of drug initiation and length of exposure to treatment, and ...